Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=927963dc-7bd9-4c0e-ab2c-5b92d55e6684&Preview=1
Date 3/31/2008
Company Name Tryton Medical, Inc.
Mailing Address 2330 Washington Street Newton, MA 02462
Company Description Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
Proceeds Purposes Dan Cole, Co-Founder and Board Member of Tryton and General Partner of Spray Venture Partners said, “This capital will allow Tryton to advance its leadership position with aggressive execution of its European commercialization strategy and clinical trial plans in the U.S.”
